Detalhe da pesquisa
1.
Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies.
Circulation
; 135(19): 1819-1831, 2017 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28249876
2.
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
Circulation
; 135(4): 338-351, 2017 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27941065
3.
Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies.
Cardiovasc Drugs Ther
; 32(4): 365-372, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30073585
4.
Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries.
Cardiovasc Drugs Ther
; 31(2): 187-195, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28466399
5.
Primary Care Physician Perspectives on Barriers to Statin Treatment.
Cardiovasc Drugs Ther
; 31(3): 303-309, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28710589
6.
Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.
Int J Clin Pract
; 71(8)2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28750477
7.
Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
Br J Clin Pharmacol
; 82(6): 1412-1443, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27478094
8.
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
Cardiovasc Drugs Ther
; 30(3): 305-13, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27240673
9.
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.
Cardiovasc Drugs Ther
; 30(3): 297-304, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26936841
10.
Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date.
Int J Clin Pract
; 70(11): 886-897, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27739167
11.
Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine.
Eur Heart J
; 40(33): 2825-2830, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30169643
12.
Development and preliminary validation of a Function IndeX for Trauma (FIX-IT).
Can J Surg
; 56(5): E114-20, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24067526
13.
Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database.
Acta Orthop
; 83(6): 653-60, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23140093
14.
Characterizing a Clinical Trial - Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction.
Clin Epidemiol
; 14: 39-49, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35046729
15.
Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
Cardiovasc Drugs Ther
; 30(5): 537, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27497929
16.
Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting.
Ther Innov Regul Sci
; 54(6): 1477-1488, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32514736
17.
Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study).
Am J Cardiol
; 122(5): 768-774, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30057227
18.
Healthcare Utilization and Statin Re-Initiation Among Medicare Beneficiaries With a History of Myocardial Infarction.
J Am Heart Assoc
; 7(10)2018 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29739799
19.
Evidence-based goals in LDL-C reduction.
Clin Res Cardiol
; 106(4): 237-248, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28124099
20.
Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.
Adv Ther
; 34(8): 1876-1896, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28717862